Resource Summary Report

Generated by T1D on Aug 1, 2026

GE: Bioacore T200 Protein Analysis System

RRID:SCR_019718
Type: Tool

Proper Citation

GE: Bioacore T200 Protein Analysis System (RRID:SCR_019718)

Resource Information

URL: https://www.gelifesciences.com/en/us/shop/protein-analysis/spr-label-free-analysis/systems/biacore-t200-p-05644

Proper Citation: GE: Bioacore T200 Protein Analysis System (RRID:SCR_019718)

Description: Biacore T200 software offers a range of tools for confident and kinetic analyses. These analyses can be performed using a multicycle approach (many samples against one ligand or when different ligands are immobilized), or alternatively, using singlecycle kinetics (fast runs without regeneration). Biacore T200 is a versatile system for high-quality characterization of molecular interactions, from ions to viruses. One platform for comprehensive characterization of molecular interactions in terms of kinetics, affinity, specificity, comparability, concentration, immunogenicity, and thermodynamics. ligand-binding assays, even for the most complex biologics Confident selection and characterization of the smallest organic compounds to large multidomain proteins Validated software meeting your regulatory expectations by supporting GxP procedures and 21 CFR Part 11 compliance

Resource Type: instrument resource

Keywords: Bioacore, Protein Analysis System, Instrument Equipment, USEDit

Availability: Commercially available

Resource Name: GE: Bioacore T200 Protein Analysis System

Resource ID: SCR_019718

Alternate IDs: Model_Number_T200

Record Creation Time: 20220129T080346+0000

Record Last Update: 20260725T190916+0000

Ratings and Alerts

No rating or validation information has been found for GE: Bioacore T200 Protein Analysis System.

No alerts have been found for GE: Bioacore T200 Protein Analysis System.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at T1D .

Barajas JM, et al. (2026) Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency. Blood cancer discovery, 7(1), 51.

Chenoweth AM, et al. (2025) An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. Cancer research, 85(22), 4521.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Lyu TT, et al. (2025) The sodium-glucose co-transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor-??. British journal of pharmacology.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3298.

Singh AK, et al. (2024) Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(7), 1293.

Day CJ, et al. (2024) The essential malaria protein PfCyRPA targets glycans to invade erythrocytes. Cell reports, 43(4), 114012.

Nakazawa K, et al. (2023) Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Cancer research communications, 3(10), 2030.

Britton R, et al. (2023) Noncanonical Activity of Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Improves Cognition and Synapse Density in Aging. eNeuro, 10(6).